<DOC>
	<DOCNO>NCT00002387</DOCNO>
	<brief_summary>To estimate difference parameter antiviral activity safety control regimen indinavir combination DMP 266 experimental regimen higher-dose indinavir combination lower-dose DMP 266 sixteen week dose , protease inhibitor- non-nucleoside reverse transcriptase inhibitor-naive , HIV-1 seropositive patient . It hypothesize 16 week randomize treatment either control experimental regimen : 1 . The observed proportion patient serum viral RNA &lt; 400 copies/ml experimental control regimen similar continue 48 week . 2 . The safety profile two group similar , judged incidence serious , drug-related adverse experience incidence event specific interest ( e.g. , nephrolithiasis , hyperbilirubinemia , nausea/vomiting , rash , CNS-related symptom ) continue 48 week . 3 . The two group similar respect change baseline serum viral RNA CD4 count continue 48 week .</brief_summary>
	<brief_title>The Safety Effectiveness Indinavir Sulfate Plus Efavirenz</brief_title>
	<detailed_description>It hypothesize 16 week randomize treatment either control experimental regimen : 1 . The observed proportion patient serum viral RNA &lt; 400 copies/ml experimental control regimen similar continue 48 week . 2 . The safety profile two group similar , judged incidence serious , drug-related adverse experience incidence event specific interest ( e.g. , nephrolithiasis , hyperbilirubinemia , nausea/vomiting , rash , CNS-related symptom ) continue 48 week . 3 . The two group similar respect change baseline serum viral RNA CD4 count continue 48 week . Patients randomize one two regimen : control regimen indinavir plus DMP 266 experimental regimen indinavir plus DMP 266 , different dos control regimen .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV1 seropositive status . CD4 count &gt; = 100 cells/mm3 . Serum viral RNA level &gt; = 10,000 copies/ml . Exclusion Criteria Prior Medication : Excluded : Prior protease inhibitor therapy . Prior nonnucleoside reverse transcriptase inhibitor therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>efavirenz</keyword>
</DOC>